Comparative Pharmacology
Head-to-head clinical analysis: MINITRAN versus NITROGLYCERIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINITRAN versus NITROGLYCERIN.
MINITRAN vs NITROGLYCERIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing cGMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing cGMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
None Documented
Clinical Note
moderateNitroglycerin + Etacrynic acid
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid."
Clinical Note
moderateNitroglycerin + Bumetanide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide."
Clinical Note
moderateNitroglycerin + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide."
Clinical Note
moderateNone Documented
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator
Nitroglycerin + Indapamide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide."